Latest Fetal hemoglobin Stories
RICHMOND, Calif., Feb. 4, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc.
Data Demonstrate Hydroxyurea Therapy Offers Safe, Effective Disease Management CINCINNATI, Nov.
New research presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans uncovers several important insights into the pathophysiology of sickle cell disease and thalassemia that may soon translate into the development of better, more targeted treatments for hundreds of thousands of patients worldwide.
A research team from Dana-Farber/Boston Children's Cancer and Blood Disorders Center and other institutions has discovered a new genetic target for potential therapy of sickle cell disease (SCD).
Treatment for sickle cell disease has largely focused on managing pain and acute complications, but current research, including several projects at Texas Children’s Hematology Center, is now aimed at developing more efficient and progressive forms of treatment that could potentially benefit patients around the world.
- A person in a secondary role, specifically the second most important character (after the protagonist).